Review
Medicine, General & Internal
Chunhong Xie, Min Wei, Feiyan Yang, Qin Liu, Fuzhen Wu, Jinxiong Huang
Summary: This meta-analysis investigated the efficacy and toxicity of carfilzomib- or bortezomib-based regimens for transplant-ineligible patients with newly diagnosed multiple myeloma. The results showed that carfilzomib-based regimens had a higher overall response rate compared to bortezomib-based regimens, but there were no improvements in progression-free survival, overall survival, and complete response rate. Carfilzomib-based regimens also showed higher toxicity.
Article
Oncology
Yujia Zhai, Dai Yuan, Xueling Ge, Shunfeng Hu, Peipei Li, Xiaosheng Fang, Ying Li, Xiangxiang Zhou, Xin Wang
Summary: The study found that in bortezomib-containing regimens, VDD had significantly higher complete response rate and very good partial response rate compared to VD subgroup. There was no significant difference in survival between VDD and VD subgroups. In vindesine-containing regimens, there was no statistical significance between vDD and vAD in terms of response rate, survival, and toxicity.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Hematology
Susan Bal, Smith Giri, Kelly N. Godby, Luciano J. Costa
Summary: The introduction of novel agents has rapidly expanded the therapeutic landscape of multiple myeloma (MM), with the assessment of minimal residual disease (MRD) serving as a powerful predictor of long-term outcomes and providing opportunities for personalized treatment approaches.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Medicine, Research & Experimental
Qiaolin Zhou, Fang Xu, Jingjing Wen, Jing Yue, Ya Zhang, Jing Su, Yiping Liu
Summary: The study aimed to analyze the efficacy and safety of sequential therapy with bortezomib-based triplet regimens without lenalidomide followed by continuous treatment with lenalidomide and dexamethasone or bortezomib and dexamethasone. The results showed that the sequential administration of bortezomib-based triplet regimens without lenalidomide followed by continuous lenalidomide and dexamethasone treatment may be as effective as the combination of bortezomib-lenalidomide-dexamethasone for first-line treatment in newly diagnosed multiple myeloma patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra Cornelisse, Rosella Troia, Stefania Oliva, Vincent van de Velden, KaLung Wu, Paula F. Ypma, Gerard Bos, Mark-David Levin, Luca Pour, Christoph Driessen, Annemiek Broijl, Alexandra Croockewit, Monique C. Minnema, Anders Waage, Cecilie Hveding, Niels W. C. J. van de Donk, Massimo Offidani, Giuseppe A. Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo
Summary: Consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and depth of response in newly diagnosed patients with multiple myeloma compared to maintenance alone.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Peter A. Forsberg, Adriana C. Rossi, Angelique Boyer, Roger N. Pearse, Karen A. Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, Scott Ely, Leora Boussi, John N. Allan, Morton Coleman, Ruben Niesvizky, Tomer M. Mark
Summary: The study evaluated a new treatment regimen for multiple myeloma called Car-BiRd and found that it can achieve similar outcomes with reduced toxicities compared to standard treatment regimens. The results showed a high overall response rate in newly diagnosed MM patients and suggest that the sequential Car-BiRd regimen is an effective and safe approach for upfront treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Review
Medicine, Research & Experimental
Thierry Facon, Jesus San-Miguel, Meletios A. Dimopoulos, Maria-Victoria Mateos, Michele Cavo, Sophie van Beekhuizen, Zijiao Yuan, Joao Mendes, Annette Lam, Jianming He, Eric Ammann, Shaji Kumar
Summary: This study compares the efficacy of different treatment options for transplant-ineligible patients with newly diagnosed multiple myeloma through a network meta-analysis. The results suggest that daratumumab-containing treatments and bortezomib/lenalidomide/dexamethasone may be more effective than continuous lenalidomide/dexamethasone.
ADVANCES IN THERAPY
(2022)
Article
Oncology
Francesco Maura, Eileen M. Boyle, David Coffey, Kylee Maclachlan, Dylan Gagler, Benjamin Diamond, Hussein Ghamlouch, Patrick Blaney, Bachisio Ziccheddu, Anthony Cirrincione, Monika Chojnacka, Yubao Wang, Ariel Siegel, James E. Hoffman, Dickran Kazandjian, Hani Hassoun, Emily Guzman, Sham Mailankody, Urvi A. Shah, Carlyn Tan, Malin Hultcrantz, Michael Scordo, Gunjan L. Shah, Heather Landau, David J. Chung, Sergio Giralt, Yanming Zhang, Arnaldo Arbini, Qi Gao, Mikhail Roshal, Ahmet Dogan, Alexander M. Lesokhin, Faith E. Davies, Saad Z. Usmani, Neha Korde, Gareth J. Morgan, Ola Landgren
Summary: This study reveals the impact of distinct genomic drivers and microenvironment changes on clinical outcome and treatment response in patients with newly diagnosed multiple myeloma treated with specific anti-CD38 antibody-containing regimens using whole-genome and single-cell RNA sequencing data.
Article
Biochemistry & Molecular Biology
Martin Stork, Sabina Sevcikova, Tomas Jelinek, Jiri Minarik, Jakub Radocha, Tomas Pika, Lenka Pospisilova, Ivan Spicka, Jan Straub, Petr Pavlicek, Alexandra Jungova, Zdenka Knechtova, Viera Sandecka, Vladimir Maisnar, Roman Hajek, Ludek Pour
Summary: This study aimed to define risk groups in newly diagnosed multiple myeloma (MM) patients with para-skeletal plasmacytomas (PS) and extramedullary plasmacytomas (EMD). The results showed that NDMM patients with low bone marrow plasma cell infiltration had an excellent prognosis in the case of PS plasmacytomas, while those with over 5% bone marrow plasma cells and 3 or more plasmacytomas had the worst prognosis.
Article
Oncology
Ola Landgren, Dickran Kazandjian, Murielle Roussel, Jagoda Jasielec, Dominik Dytfeld, Aparna Anderson, Tara A. Kervin, Karim Iskander, Ian McFadden, Andrzej J. Jakubowiak
Summary: This pooled analysis of four studies evaluated the clinical effectiveness of KRd in newly diagnosed multiple myeloma patients. The results showed that KRd is an effective and tolerable treatment option for patients regardless of autologous stem cell transplant eligibility.
LEUKEMIA & LYMPHOMA
(2022)
Review
Pharmacology & Pharmacy
Radowan A. Elnair, Sarah A. Holstein
Summary: Multiple myeloma (MM) is considered incurable, but advancements in treatment options over the past 20 years have led to improved response rates and survival rates. Induction regimens have evolved from alkylator-based therapies to those consisting of immunomodulatory drugs and proteasome inhibitors. Standard regimens have emerged for both transplant-eligible and transplant-ineligible patient populations.
Review
Oncology
Vasileios Georgoulis, Anna-Bettina Haidich, Konstantinos I. Bougioukas, Eleftheria Hatzimichael
Summary: This overview presents a summary of systematic reviews on the safety and efficacy of carfilzomib in multiple myeloma. The results show that carfilzomib is effective in relapsed/refractory multiple myeloma, but is associated with cardiovascular adverse events, nephrotoxicity, and serious infections.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. B. Lahoud, Heather J. J. Landau, David J. J. Chung, Gunjan L. L. Shah, Michael Scordo, Sergio A. A. Giralt, Alexander Lesokhin, Saad Z. Z. Usmani, Ola Landgren, Neha Korde
Summary: This retrospective study compared the efficacy and safety of VRd and KRd as induction regimens. The results showed that KRd was associated with improved progression-free survival (PFS) and event-free survival (EFS) compared to VRd, with a more significant improvement observed in high-risk patients.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Niels W. C. J. van de Donk
Summary: The evaluation of circulating plasma cells in newly diagnosed multiple myeloma patients is essential to differentiate between MM and pPCL. A new study challenges the current threshold of >= 5% circulating plasma cells and suggests that a threshold of 2% circulating tumor cells may identify a subset of ultra-high-risk MM patients with comparable prognosis as pPCL. This finding has implications for treatment decisions and clinical trial enrollment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
